Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 21, 2026
TickeronGET DAILY SIGNALS
Cardiff Oncology (CRDF): Analyst Targets Signal Potential for +840% Gains to $8

Cardiff Oncology (CRDF): Analyst Targets Signal Potential for +840% Gains to $8

Key Takeaways

  • The central $8 target represents the arithmetic mean of four recent analyst price targets from H.C. Wainwright ($9), Piper Sandler ($6), Lucid Capital ($4), and Noble Financial ($12), rounded from a calculated mean of roughly $7.75.
  • At a recent price near $0.85, reaching $8 would require a gain of roughly 840%—a substantial move for a company now valued around $66 million.
  • The analyst target range is unusually wide, from $4 to $12, highlighting significant disagreement about the company's clinical and financing outlook.
  • The strongest support comes from positive Phase 2 data for onvansertib and a successful End-of-Phase 2 meeting with the FDA ahead of a planned registrational trial.
  • The biggest risks are a short cash runway, likely shareholder dilution from an upcoming financing, and the fact that onvansertib's PLK1 mechanism remains clinically unproven.
  • You can find more detail on the ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages that track these developments.

Analyst Price Targets and Consensus View

Cardiff Oncology, Inc. (CRDF) is a clinical-stage biotechnology company developing onvansertib, an oral PLK1 inhibitor, for first-line RAS-mutated metastatic colorectal cancer (mCRC). Four recent, individually identifiable analyst price targets were reviewed: H.C. Wainwright's Robert Burns set $9 (Buy, November 2026), Piper Sandler set $6 (Buy, August 2026), Lucid Capital set $4 (Buy, June 2026), and Noble Financial set $12 (Buy, May 2026). The arithmetic mean is approximately $7.75, which is rounded to a central target of $8. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The range of $4 to $12 is extremely wide—the highest target is three times the lowest—signaling that analysts disagree sharply about valuation. Several firms, including William Blair, TD Cowen, and Craig-Hallum, hold neutral (Hold) ratings without publishing current price targets. Notably, H.C. Wainwright upgraded the stock to Buy from Neutral in September 2026, while Lucid Capital cut its target to $4 from $10 in June 2026. Different data providers report slightly different averages (TipRanks shows a five-analyst figure near $7.50, while S&P Global data points lower), reflecting how quickly targets have been trimmed as the share price fell. No single target should be read as a forecast of where the stock will trade.

Current Market Position and Path Toward the Target

CRDF recently traded near $0.85, toward the bottom of a 52-week range of $0.71 to $3.31. Reaching the $8 central target implies an upside of roughly 840%, which must be described as a very large move. The stock has fallen sharply over the past year—by roughly 59%—even as the company reported positive clinical data, leaving its market capitalization near $66 million.

A path toward the target would likely require several steps to succeed in sequence: securing financing to initiate a Phase 3 trial, enrolling patients, and ultimately generating confirmatory efficacy data that supports an eventual regulatory filing. Because the company is pre-revenue at commercial scale (trailing revenue of roughly $559,000) and unprofitable, the valuation is driven almost entirely by clinical and regulatory milestones rather than current fundamentals.

What Could Support a Move Toward the Target

The central clinical catalyst is the Phase 2 CRDF-004 trial. In first-line RAS-mutated mCRC, the 30 mg onvansertib plus FOLFIRI/bevacizumab arm showed a confirmed objective response rate (ORR) of 72.2% versus 42.1% for standard of care, with a progression-free survival hazard ratio of 0.55 and no additive toxicity. Cardiff completed a successful End-of-Phase 2 meeting with the FDA and aligned on a Phase 3 registrational design, positioning onvansertib for a large, underserved patient population with few targeted treatment options. Positive clinical updates, a well-received financing, or a partnership could all reinforce the bull case.

What Could Prevent the Target From Being Reached

The most immediate constraint is capital. With cash near $34 million and a quarterly burn of roughly $12 million, the runway extends only into the first quarter of 2027, and management has said Phase 3 initiation is subject to securing additional financing—raising the risk of shareholder dilution. Onvansertib's PLK1 mechanism also has no approved therapies to validate it, and Phase 2 data came from a small patient sample that may not replicate in a larger trial. A dilutive raise, a clinical setback, or a delay in Phase 3 could keep the shares depressed well below $8.

Technical Levels and Market Structure

The shares sit just above their 52-week low of $0.71, a key support level. A breakdown below that level would mark a fresh multi-year low, while the round $1.00 mark and the prior trading zones in the low single digits now act as overhead resistance. The broader structure remains a downtrend from the $3.31 high, so any sustained recovery would first need to reclaim $1.00 and hold above it before higher targets become technically relevant.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary. The most important near-term items are the detailed Phase 3 trial design and any financing announcement, the planned Phase 3 initiation targeted for the first quarter of 2027, additional durability data from CRDF-004, and quarterly cash and burn disclosures. Investors should also watch analyst revisions, which have moved frequently as the stock declined.

AI Daily Buy/Sell Signals

When evaluating a volatile, catalyst-driven stock like this, I find it helpful to review Tickeron's AI Daily Buy/Sell Signals. These tools apply artificial intelligence to monitor thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on technical behavior and shifting market conditions. For names where clinical milestones can drive sharp moves, such signals offer a structured way to track momentum changes alongside traditional analysis.

Final Assessment

The $8 central target, derived from averaging four recent analyst price targets, is far above the current price and would require a gain of roughly 840%. That gap largely reflects how quickly the stock has fallen and how slowly analyst targets have adjusted, rather than a near-term expectation. Support rests on genuinely encouraging Phase 2 onvansertib data and FDA alignment on a Phase 3 path, while the principal obstacles are financing risk, dilution, and unproven clinical efficacy at registrational scale. With targets ranging from $4 to $12 and several firms on Hold, the outlook is genuinely contested. Investors should monitor the Phase 3 design, financing terms, and trial initiation rather than treat the $8 figure as a near-term destination.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CRDF

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CRDF's Indicator enters downward trend

The Aroon Indicator for CRDF entered a downward trend on November 20, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 252 similar instances where the Aroon Indicator formed such a pattern. In 215 of the 252 cases the stock moved lower. This puts the odds of a downward move at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRDF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CRDF's RSI Oscillator exited the oversold zone, 24 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 58 cases where CRDF's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on CRDF as a result. In 76 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

The Moving Average Convergence Divergence (MACD) for CRDF just turned positive on November 16, 2026. Looking at past instances where CRDF's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.

Following a +6.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRDF advanced for three days, in 208 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

CRDF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. CRDF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.332) is normal, around the industry mean (3.596). P/E Ratio (-1.326) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (178.571) is also within normal values, averaging (443.347).

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRDF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors

Industry Biotechnology

Industry
N/A
Address
11055 Flintkote Avenue
Phone
+1 858 952-7570
Employees
31
Web
https://www.cardiffoncology.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.